Maverick Ventures

Maverick Ventures is the venture capital arm of Maverick Capital, a multi-billion dollar hedge fund platform managing approximately $12.5 billion in AUM. Founded in 2015 in San Francisco, Maverick Ventures operates as an evergreen fund structurally integrated with the hedge fund platform, giving portfolio companies access to hedge-fund-grade analysts and public company networks that conventional VC firms cannot match. By March 2025, the firm had raised over $240 million for its fourth vintage — led by Kindred Capital with Y Combinator, Rebel Fund, and Concept Ventures joining — bringing total capital raised to $855 million and AUM to $1.4 billion. Managing Partner David Singer, a repeat founding CEO of three public companies, leads a deliberate five-person investing team that backs only a select number of companies per year to enable deep engagement with each founder. The firm focuses on healthcare innovation and enterprise AI, investing from Seed through Series C and beyond with check sizes typically between $3 million and $50 million. Maverick leads rounds. Across 83 total investments, the portfolio has produced 10 unicorns, 12 IPOs, and 37 acquisitions. Notable exits include Hims and Hers (seed investor through its 2021 IPO), BioCatch (sold to Permira for $1.3 billion in 2024), Coupang, One Medical, and Tata 1mg. Recent investments include Oula Health ($28 million Series B co-led, December 2024) and Garner (healthcare technology, February 2026). Approximately 30 percent of fund capital comes from Maverick partners and employees — the largest single LP — a structural feature that aligns the partnership's own capital with founder outcomes. Maverick's integration with a mature public markets platform allows it to support companies from first institutional check through post-IPO holding, providing continuity of partnership that few venture platforms can offer.